{"brief_title": "A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", "brief_summary": "The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.", "detailed_description": "Patients will be given combination treatment with efavirenz, stavudine, and lamivudine.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Efavirenz", "Lamivudine", "Stavudine"], "criteria": "Inclusion Criteria Patients must have: - Documented diagnosis of HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml. - Life expectancy of at least 12 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Current bilateral peripheral neuropathy greater than or equal to Grade 2. - Proven or suspected acute hepatitis due to any cause. - Recurrent episodes of moderate to severe diarrhea, or vomiting lasting for more than 4 days within 3 months prior to dosing. - Hypersensitivity to any component of the formulation of efavirenz, stavudine, or lamivudine. - Any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values). - Any clinically significant disease (other than HIV infection) or clinically significant findings found during the screening of medical history or physical examination. - Any malignancy that requires systemic therapy. - Any active AIDS-defining opportunistic infection or disease. Concurrent Medication: Excluded: Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine or any medications contraindicated for concomitant use with stavudine or lamivudine as described in the current information package insert. Patients with the following prior conditions are excluded: - History of acute or chronic pancreatitis. - A life expectancy of less than 12 months. - Difficulty swallowing capsules/tablets. - Inability to communicate effectively with study personnel. Prior Medication: Excluded: - Any other experimental drug within 30 days of introducing study treatment. - Vaccination within 3 weeks of screening visit. - Any prior antiretroviral therapy. - Interferon started within 30 days of initiating study treatment. Risk Behavior: Excluded: Current alcohol or illicit drug use which interferes with patient's ability to follow study regimen.", "gender": "All", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "efavirenz", "mesh_term": ["HIV Infections", "Stavudine", "Efavirenz", "Lamivudine"], "id": "NCT00002227"}